SPY315.89-1.17 -0.37%
DIA260.74-2.26 -0.86%
IXIC10,432.33-1.32 -0.01%

BMO Capital Downgrades Intercept Pharmaceuticals to Market Perform, Lowers Price Target to $52

BMO Capital analyst Matthew Luchini downgrades Intercept Pharmaceuticals (NASDAQ:ICPT) from Outperform to Market Perform and lowers the price target from $107 to $52.

Benzinga · -
BMO Capital analyst Matthew Luchini downgrades Intercept Pharmaceuticals (NASDAQ: ICPT) from Outperform to Market Perform and lowers the price target from $107 to $52.